Takeo Minaguchi

ORCID: 0000-0003-3577-5124 · 5 papers in corpus
2022
World journal of surgical oncology ·doi:10.1186/s12957-022-02600-7

BackgroundOvarian clear cell carcinoma (OCCC) is one of the most lethal types of ovarian cancer. Early-stage OCCC can be cured by surgery; however, advanced-stage disease shows poor prognosis due to chemoresistance unlike the more common hi…

article 2016

Dienogest is a novel synthesized progestin used for treatment of endometriosis. This is the first case report describing a therapeutic effect of dienogest on a gynecologic malignancy. The patient was a 44-year-old woman with advanced adenos…

article 2016
International cancer conference journal ·doi:10.1007/s13691-016-0271-9

A patient who underwent fertility-sparing surgery for Stage IA clear cell carcinoma may have developed de novo clear cell carcinoma in the contralateral ovary 9 years later. She underwent fertility-sparing surgery and postoperative adjuvant…

other 2013
SpringerPlus ·doi:10.1186/2193-1801-2-618

Dienogest is a novel synthesized progestin used for treatment of endometriosis. This is the first case report describing a therapeutic effect of dienogest on a gynecologic malignancy. The patient was a 44-year-old woman with advanced adenos…

article 2006
·doi:10.1016/j.canlet.2006.06.013

Young patients with complex atypical hyperplasia (CAH) or stage Ia, G1 adenocarcinoma (IaG1) of the endometrium, who desire to preserve fertility, can select the conservative therapy by oral progestin, medroxyprogesterone acetate (MPA). How…